

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 02-134-D)**

In re Application of:)	
)	
A. Lavie et al.)	
)	Examiner: Lei Yao
Serial No. 10/791,155)	
)	Group Art Unit: 1642
Filed: March 1, 2004)	
)	Confirmation No. 3822
For: Use of Specifically Engineered Enzymes)	
To Enhance the Efficacy of Prodrugs)	
)	

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In order to comply with the duty of disclosure under 37 C.F.R. 1.56 in compliance with 37 CFR §§1.97 and 1.98, attached hereto is Form PTO-1449, and a copy of the document listed thereon. The document contains information which the Examiner may consider to be important in deciding whether to allow the present application to issue as a patent.

Foreign Patent Application Publication Document

1. WO 2002/083892 Marliere et al. published October 24, 2002

Applicants have submitted on January 2, 2008 U.S. Patent Application Publication No. 2007/0037269 (the '269 publication) published from U.S. Patent Application No. 11/132,445 (the '445 application). The '445 application is a continuation of the U.S. national phase of the above-mentioned PCT application. Although the disclosure of WO 2002/083892 should be identical to that of the '269 publication, and no representation is hereby intended that they are identical, 35 U.S.C.

102 may be applied differently to the '269 publication and WO 2002/083892 based on their filing and publication dates.

In accordance with MPEP Sections 609 and 707.05(b), it is requested that each document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing on Form PTO-1449. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

The present Disclosure Statement is being submitted in compliance with 37 CFR 1.56 insofar as an Examiner might consider the cited document important in deciding whether to allow the application to issue as a patent, but the citation of the document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner, in the normal course of examination, will make an independent search and will determine the best prior art consistent with 37 CFR 1.104(a) and 1.106(b) and, in the course of each search, will review for relevance every document cited on the attached form even if not initialed.

It is believed that no further fee is due in connection with this filing; however, if a fee is due the Commissioner is authorized to charge our deposit account 13-2490.

Respectfully submitted,

Date: January 24, 2008

/Y. Elaine Chang/
Y. Elaine Chang
Registration No. 54,698

McDonnell Boehnen Hulbert & Berghoff LLP
300 South Wacker Drive, Suite 3100
Chicago, Illinois 60606
Telephone : (312) 913-0001
Facsimile : (312) 913-0002